Cerevel Therapeutics Holdings, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020
ASSETS
Current assets:
Cash
Prepaid expenses
Cash and cash equivalents
Marketable securities
Prepaid expenses and other current assets
Total current assets

Marketable securities held in Trust Account
Marketable securities
Property and equipment, net
Operating lease assets
Restricted cash
Other long-term assets
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accrued expenses
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities, current portion
Total current liabilities

Deferred underwriting commissions
Operating lease liabilities, net of current portion
Financing liability, related party (Notes 5 and 6)
Financing liability (Notes 5 and 6)
Financing liability, related party (Notes 5, 7 and 15)
Financing liability (Notes 5 and 7)
2027 convertible senior notes, net (Note 6)
Other long-term liabilities
Total liabilities
Class A ordinary shares, $0.0001 par value; 13,725,029 shares subject to possible redemption at $10.00 per share
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value: 500,000,000 shares authorized; 181,888,631 and 181,362,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Class A Ordinary Shares
Class B Ordinary Shares
Total common stock, $0.0001 par value: 500,000,000 shares authorized; 181,888,631 and 181,362,064 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders’ equity

Total liabilities and stockholders’ equity

Comments